title: An assessment by the Statin Liver Safety Task Force: 2014 update.
abstract: In the 2006 Report of the National Lipid Association's Statin Safety Task Force, a panel of experts in hepatology published their findings on specific questions related to the liver blood testing during statin therapy. Among their recommendations was that regulatory agencies reconsider the statin-labeling recommendation at that time, which required post-statin liver enzyme testing. Since then, the Food and Drug Administration altered statin labeling such that unless clinically indicated for other reasons, after a pre-statin therapy baseline evaluation, follow-up liver enzyme testing was not uniformly required after statin initiation. This 2014 report provides an update on interim issues relevant to statins and liver safety. Some of the points discussed include the value of baseline liver enzymes before initiating statin therapy, safety of statin use in patients with nonalcoholic fatty liver disease, potential drug interactions between statins and drugs used to treat hepatitis, the use of statins in liver transplant recipients, and the use of statins in patients with autoimmune liver disease. Finally, this panel provides diagnostic and algorithmic approaches when evaluating statin-treated patients who experience elevations in liver enzymes.
authors.affiliation: Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. Electronic address: hbaysmd@aol.com.
authors.forename: Harold
authors.initials: H
authors.lastname: Bays
authors.affiliation: Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: David E
authors.initials: DE
authors.lastname: Cohen
authors.affiliation: Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Naga
authors.initials: N
authors.lastname: Chalasani
authors.affiliation: Brooke Army Medical Center, University of Texas Health Center San Antonio, Uniformed Services University of the Health Sciences, San Antonio, TX, USA.
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Harrison
authors.lastname: The National Lipid Association's Statin Safety Task Force
mesh_terms: D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control*; D019317:Evidence-Based Medicine; D019693:Hepatitis, Autoimmune / Q000150:complications; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008107:Liver Diseases / Q000209:etiology; D008111:Liver Function Tests; D016031:Liver Transplantation; D065626:Non-alcoholic Fatty Liver Disease / Q000150:complications; D014777:Virus Diseases / Q000150:complications / Q000188:drug therapy
chemical_list: D000998:Antiviral Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Cholesterol; Lipid; Liver; National Lipid Association; Statin